Jazz Pharmaceuticals
JAZZ
417 hedge funds and large institutions have $6.52B invested in Jazz Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 155 increasing their positions, 128 reducing their positions, and 66 closing their positions.
26% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 66
21% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 128
3% more funds holding
Funds holding: 403 → 417 (+14)
4.06% less ownership
Funds ownership: 92.07% → 88.02% (-4.1%)
30% less capital invested
Capital invested by funds: $9.34B → $6.52B (-$2.81B)
31% less call options, than puts
Call options by funds: $18M | Put options by funds: $26.1M
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$69.2M |
| 2 |
SI
Scout Investments
Kansas City,
Missouri
|
+$65.4M |
| 3 |
CGM
Capital Growth Management
Boston,
Massachusetts
|
+$49M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$45M |
| 5 |
Renaissance Technologies
New York
|
+$37.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$184M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$172M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$161M |
| 4 |
O
OrbiMed
New York
|
-$149M |
| 5 |
SIG
Senator Investment Group
New York
|
-$91.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WC
476
Whitney & Co
Rochester,
New York
| – | -$14K | -100 | Closed |
|
|
ML
477
McAdam LLC
Philadelphia,
Pennsylvania
| – | -$10K | -62 | Closed |
|
|
IP
478
Intellectus Partners
San Francisco,
California
| – | -$3K | -16 | Closed |
|
|
OGC
479
Oak Grove Capital
North Hampton,
New Hampshire
| – | -$1K | -8 | Closed |
|
480
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | -6 | Closed |
|
|
TWA
481
TCI Wealth Advisors
Tucson,
Arizona
| – | -$1K | -3 | Closed |
|
|
SAM
482
Shamrock Asset Management
Dallas,
Texas
| – | +$148 | +1 | New |
|
483
Fifth Third Bancorp
Cincinnati,
Ohio
| – | +$297 | +2 | New |
|
|
PFGIA
484
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| – | +$297 | +2 | New |
|
JAZZ Hedge Fund Activity: Q4 2018 in Review
417 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2018, worth a combined $6.52B — down 30% from $9.34B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new JAZZ positions and 66 closed out — a net gain of 17 holders — while 155 added to existing stakes and 128 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $69.2M. The largest seller was Putnam Investments, cutting an estimated $184M.
- 417 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2018, up from 403 in Q3 2018.
- Funds reported $6.52B of Jazz Pharmaceuticals stock for Q4 2018, down 30% quarter-over-quarter.
- 83 funds opened new Jazz Pharmaceuticals positions in Q4 2018 and 66 closed out, a net change of +17 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2018 was LSV Asset Management, an estimated $69.2M added.
- The largest Jazz Pharmaceuticals seller in Q4 2018 was Putnam Investments, an estimated $184M sold.
Based on aggregated 13F filings for Q4 2018.